PFD Capital Partners has announced the closing of PFD Select Medical Receivables 1018, LLC (“PFDSMR1018”), marking another important milestone in the continued development of the company’s 1000 Series.
PFDSMR1018 is the 17th special purpose entity in PFD’s 1000 Series, which is focused on Personal Injury Medical Accounts Receivable financing. The entity launched on March 11, 2026, and officially closed to new investments on May 18, 2026, with participation from 99 investors.
Of those investors, 75 were new to PFD, including 34 referral-based investors. An additional 24 were existing PFD investors who elected to participate again in the 1000 Series.
For PFD, this closing represents more than the completion of another offering. It reflects continued investor engagement, growing awareness of the platform, and the steady expansion of a specialized healthcare finance model designed to support both medical service providers and participating investors.
“Closing PFDSMR1018 represents another meaningful milestone for PFD and the continued development of the 1000 Series,” said Gary L. Ermoian, Co-Founder and Chief Operating Officer of PFD Capital Partners, Inc. “We are encouraged by the combination of new participation and repeat participation from existing investors, which reflects the continued expansion of our platform and the long-term relationships we have worked to build.”
Supporting Medical Service Providers Through Specialty Finance
At the core of PFD’s platform is a practical challenge faced by many medical service providers: delayed receivable recovery.
Through its affiliated platform, including PFD Management, LLC, PFD provides financing solutions to medical service providers that hold Personal Injury Medical Accounts Receivable. By helping providers convert receivables into usable working capital, PFD supports provider liquidity and helps medical service providers continue operating with greater financial flexibility.
This is an important part of the healthcare-linked specialty finance market.
Medical providers often deliver care long before receivables are resolved. That timing gap can create financial pressure, particularly for providers serving patients whose treatment is tied to personal injury matters. PFD’s model is designed to help address that gap by creating liquidity in a specialized segment of the medical receivables market.
“PFD’s work with MSPs is centered on converting delayed medical receivables into usable working capital,” Ermoian added. “That process supports healthcare providers, creates liquidity in a specialized segment of the medical receivables market and allows PFD to continue building a differentiated specialty finance platform.”
A Platform Built Around Structure and Process
The closing of PFDSMR1018 also highlights the importance of infrastructure behind PFD’s work.
PFD Management’s operating platform includes originations, underwriting, analytics, funding coordination, servicing, collections support, portfolio administration, and investor reporting. Each of these functions plays a role in how the company evaluates receivable portfolios, provider relationships, documentation, and transaction structure.
In a market connected to healthcare, finance, legal coordination, and compliance, process matters.
PFD’s continued growth is supported by the company’s focus on disciplined portfolio administration and operational consistency. As the platform expands, maintaining structure, communication, and oversight remains central to the company’s approach.
To date, PFD is managing over $2 billion in receivables, supported by more than 1,000 individual portfolio transactions. The company has assisted medical service providers connected to over 250,000 patients and has raised or deployed over $360 million in capital across its platform.
These figures reflect the scale of the company’s work across the healthcare finance ecosystem and the continued demand for solutions designed to support provider liquidity.
Why PFDSMR1018 Matters
PFDSMR1018 is notable not only because it is the 17th SPE in the 1000 Series, but also because of the investor participation behind it.
The involvement of 99 investors, including 75 new investors and 24 repeat investors, reflects continued interest in PFD’s healthcare-linked specialty finance platform. Referral-based participation also remains meaningful, with 34 new investors joining through referrals.
For any growing investment platform, repeat participation and referral activity are important signals.
They suggest that relationships are continuing to develop, investors are staying engaged, and the platform is reaching new audiences through existing networks. For PFD, that kind of relationship-driven growth aligns closely with the company’s long-term view of investor communication, transparency, and trust.
The 1000 Series is structured to provide participating investors with exposure to portfolios of medical receivables originated through PFD’s platform, with a targeted fixed preferred return as described in applicable offering materials. Targeted returns are not guaranteed, and all investments involve risk, including possible loss of principal.
Continuing to Build a Differentiated Healthcare Finance Platform
PFD Capital Partners operates at the intersection of specialty finance and healthcare.
The company’s core work focuses on providing capital to medical service providers through the financing of personal injury-related medical receivables. This model supports provider liquidity while allowing PFD to continue building a platform around originations, underwriting, receivable management, servicing, and investor reporting.
Beyond medical receivables financing, PFD has also expanded into selective healthcare innovation through strategic participation in high-potential medical ventures. Together, these areas reflect the company’s broader view of healthcare as an ecosystem where capital, access, provider stability, innovation, and long-term value creation are closely connected.
The closing of PFDSMR1018 reinforces that direction.
It represents continued execution within the 1000 Series, continued investor participation, and continued platform growth within a specialized segment of the healthcare finance market.
As PFD looks ahead, the company remains focused on disciplined growth, responsible portfolio administration, provider support, investor communication, and long-term platform development.
PFDSMR1018 is another step in that process.
Not simply because another SPE has closed, but because it reflects the continued momentum behind PFD’s broader mission: building a specialty finance platform designed to support medical providers, serve a complex healthcare ecosystem, and create structured opportunities for participating investors.